SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* GL Partners Capital Management Ltd (Last) (First) (Middle) UNIT 3001, CHINA WORLD TOWER 2, NO. 1 JIAN GUO MEN WAI AVENUE (Street) BEIJING F4 100004 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 02/22/2016	3. Issuer Name and Ticker or Trading Symbol SCICLONE PHARMACEUTICALS INC [ SCLN ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value $0.001 per share	4,750,116	I	See Footnote(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person* GL Partners Capital Management Ltd (Last) (First) (Middle) UNIT 3001, CHINA WORLD TOWER 2, NO. 1 JIAN GUO MEN WAI AVENUE (Street) BEIJING F4 100004 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* GL CAPITAL MANAGEMENT GP Ltd (Last) (First) (Middle) UNIT 3001, CHINA WORLD TOWER 2 NO. 1 JIAN GUO MEN WAI AVENUE (Street) BEIJING F4 100004 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

Explanation of Responses:

1. 4,750,116 shares of the common stock of Sciclone Pharmaceutical, Inc. (the "Company") are owned by GL Trade Investment Limited ("GL Trade"). GL China Opportunities Fund L.P. ("GL Fund") owns 100% of the voting interests in GL Trade. GL Capital Management GP L.P. ("GL Capital") is the general partner of GL Fund. GL Capital Management GP Limited ("GL Management") is the general partner of GL Capital. GL Partners Capital Management Limited owns 51% of the voting interests in GL Management. On the basis of the foregoing relationship, each of GL Trade, GL Fund, GL Capital, GL Management and GL Partners Capital Management Limited may be deemed a beneficial owner of the Company's common stock owned by GL Trade, but each such person disclaims beneficial ownership of such shares of common stock except to the extent of such person's pecuniary interest therein, if any.

Remarks:

GL Management may be considered a member of a group beneficially owning more than 10% of the Company's common stock for purposes of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934. Neither the filing of this Form 3 nor any of its contents shall be deemed to constitute an admission by GL Management, GL Partners Capital Management Limited, or any other person that any such group exists and each of GL Management and GL Partners Capital Management Limited expressly disclaims the existence of such a group.

	GL Partners Capital Management Limited by /s/ Li Zhenfu, Director	02/26/2016
	GL Capital Management GP Limited by /s/ Li Zhenfu, Director	02/26/2016
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.